@article{362f0094c77c498d99dd9e6879c64335,
title = "Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy",
keywords = "Non-small cell lung cancer, Kirsten rat sarcoma, Mono-immunotherapy, PREDICTIVE-VALUE, CANCER, EFFICACY, INHIBITORS, DOCETAXEL, SURVIVAL, THERAPY",
author = "A.L. Noordhof and R.A.M. Damhuis and L.E.L. Hendriks and {de Langen}, A.J. and W. Timens and B.J.W. Venmans and {van Geffen}, W.H.",
year = "2021",
month = may,
day = "1",
doi = "10.1016/j.lungcan.2021.04.001",
language = "English",
volume = "155",
pages = "163--169",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
}